Droxidopa for the treatment of neurogenic orthostatic hypotension and other symptoms of neurodegenerative disorders

Bibliography

• Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci 2011;16:46-8
   Google Scholar
• Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med 2008;358:615-24
   PubMed Web of Science ®Google Scholar
• Pavy-Le TA, Amarenco G, Duerr S, et al. The movement disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension. Mov Disord 2011;26:1985-92
   PubMed Web of Science ®Google Scholar
• Moya A, Sutton R, Ammirati F, et al. Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J 2009;30:2631-71
   PubMed Web of Science ®Google Scholar
• Allcock LM, Kenny RA, Mosimann UP, et al. Orthostatic hypotension in Parkinson's disease: association with cognitive decline? Int J Geriatr Psychiatry 2006;21:778-83
   PubMed Web of Science ®Google Scholar
• Fedorowski A, Stavenow L, Hedblad B, et al. Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals (the malmo preventive project). Eur Heart J 2010;31:85-91
   PubMed Web of Science ®Google Scholar
• Rose KM, Eigenbrodt ML, Biga RL, et al. Orthostatic hypotension predicts mortality in middle-aged adults: the atherosclerosis risk in communities (ARIC) study. Circulation 2006;114:630-6
   PubMed Web of Science ®Google Scholar
• Azidah AK, Hasniza H, Zunaina E. Prevalence of falls and its associated factors among elderly diabetes in a tertiary center, Malaysia. Curr Gerontol Geriatr Res 2012;2012:539073
   PubMedGoogle Scholar
• Verwoert GC, Mattace-Raso FU, Hofman A, et al. Orthostatic hypotension and risk of cardiovascular disease in elderly people: the Rotterdam study. J Am Geriatr Soc 2008;56:1816-20
   PubMed Web of Science ®Google Scholar
• Gupta V, Lipsitz LA. Orthostatic hypotension in the elderly: diagnosis and treatment. Am J Med 2007;120:841-7
   PubMed Web of Science ®Google Scholar
• Wenning GK, Colosimo C, Geser F, et al. Multiple system atrophy. Lancet Neurol 2004;3:93-103
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Rey MV, Fabre N, et al. Factors related to orthostatic hypotension in Parkinson's disease. Parkinsonism Relat Disord 2012;18:501-5
   PubMed Web of Science ®Google Scholar
• Garland EM, Hooper WB, Robertson D. Pure autonomic failure. Handb Clin Neurol 2013;117:243-57
   PubMedGoogle Scholar
• Kaufmann H, Nahm K, Purohit D, et al. Autonomic failure as the initial presentation of parkinson disease and dementia with Lewy bodies. Neurology 2004;63:1093-5
   PubMed Web of Science ®Google Scholar
• Low PA, Singer W. Management of neurogenic orthostatic hypotension: an update. Lancet Neurol 2008;7:451-8
   PubMed Web of Science ®Google Scholar
• Saito S, Shioda K, Nishijima K. Dopamine dysregulation syndrome including mania related to coadministration of droxidopa. J Clin Psychopharmacol 2012;32:428-9
   PubMed Web of Science ®Google Scholar
• FDA approves Northera to treat neurogenic orthostatic hypotension. Washington DC: Food And Drug Administration, 2014. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm386311.htm [Last accessed 24 February 2014]
   Google Scholar
• Guyton AC, Coleman TG, Cowley AW Jr, et al. Systems analysis of arterial pressure regulation and hypertension. Ann Biomed Eng 1972;1:254-81
   PubMed Web of Science ®Google Scholar
• Osborn JW. Hypothesis: set-points and long-term control of arterial pressure. A theoretical argument for a long-term arterial pressure control system in the brain rather than the kidney. Clin Exp Pharmacol Physiol 2005;32:384-93
   PubMed Web of Science ®Google Scholar
• Low PA. Prevalence of orthostatic hypotension. Clin Auton Res 2008;18(Suppl 1):8-13
   PubMed Web of Science ®Google Scholar
• Poon IO, Braun U. High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther 2005;30:173-8
   PubMed Web of Science ®Google Scholar
• Rutan GH, Hermanson B, Bild DE, et al. Orthostatic hypotension in older adults. The cardiovascular health study. CHS collaborative research group. Hypertension 1992;19:508-19
   PubMed Web of Science ®Google Scholar
• Pathak A, Lapeyre-Mestre M, Montastruc JL, et al. Heat-related morbidity in patients with orthostatic hypotension and primary autonomic failure. Mov Disord 2005;20:1213-19
   PubMed Web of Science ®Google Scholar
• Narkiewicz K, Cooley RL, Somers VK. Alcohol potentiates orthostatic hypotension : implications for alcohol-related syncope. Circulation 2000;101:398-402
   PubMed Web of Science ®Google Scholar
• Ha AD, Brown CH, York MK, et al. The prevalence of symptomatic orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism. Parkinsonism Relat Disord 2011;17:625-8
   PubMed Web of Science ®Google Scholar
• Kamaruzzaman S, Watt H, Carson C, et al. The association between orthostatic hypotension and medication use in the british women's heart and health study. Age Ageing 2010;39:51-6
   PubMed Web of Science ®Google Scholar
• Hussain IF, Brady CM, Swinn MJ, et al. Treatment of erectile dysfunction with sildenafil citrate (viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001;71:371-4
   PubMed Web of Science ®Google Scholar
• Haapaniemi TH, Kallio MA, Korpelainen JT, et al. Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease. J Neurol 2000;247:868-74
   PubMed Web of Science ®Google Scholar
• Kujawa K, Leurgans S, Raman R, et al. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch Neurol 2000;57:1461-3
   PubMed Web of Science ®Google Scholar
• Mehagnoul-Schipper DJ, Boerman RH, Hoefnagels WH, et al. Effect of levodopa on orthostatic and postprandial hypotension in elderly parkinsonian patients. J Gerontol A Biol Sci Med Sci 2001;56:M749-M55
   PubMed Web of Science ®Google Scholar
• Goldstein DS, Eldadah BA, Holmes C, et al. Neurocirculatory abnormalities in parkinson disease with orthostatic hypotension: independence from levodopa treatment. Hypertension 2005;46:1333-9
   PubMed Web of Science ®Google Scholar
• Heinonen EH, Myllyla V. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease. Drug Saf 1998;19:11-22
   PubMed Web of Science ®Google Scholar
• Emilien G, Maloteaux JM, Geurts M, et al. Dopamine receptors--physiological understanding to therapeutic intervention potential. Pharmacol Ther 1999;84:133-56
   PubMed Web of Science ®Google Scholar
• Zeng C, Zhang M, Asico LD, et al. The dopaminergic system in hypertension. Clin Sci (Lond) 2007;112:583-97
   PubMed Web of Science ®Google Scholar
• Gomez Mde J, Rousseau G, Nadeau R, et al. Functional and autoradiographic characterization of dopamine D2-like receptors in the guinea pig heart. Can J Physiol Pharmacol 2002;80:578-87
   PubMed Web of Science ®Google Scholar
• Montastruc JL, Rascol O, Senard JM. Current status of dopamine agonists in Parkinson's disease management. Drugs 1993;46:384-93
   PubMed Web of Science ®Google Scholar
• Bonuccelli U, Lucetti C, Del DP, et al. Orthostatic hypotension in de novo parkinson disease. Arch Neurol 2003;60:1400-4
   PubMed Web of Science ®Google Scholar
• Haensch CA, Lerch H, Jorg J, et al. Cardiac denervation occurs independent of orthostatic hypotension and impaired heart rate variability in Parkinson's disease. Parkinsonism Relat Disord 2009;15:134-7
   PubMed Web of Science ®Google Scholar
• Senard JM, Rai S, Lapeyre-Mestre M, et al. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63:584-9
   PubMed Web of Science ®Google Scholar
• Oka H, Mochio S, Yoshioka M, et al. Evaluation of baroreflex sensitivity by the sequence method using blood pressure oscillations and R-R interval changes during deep respiration. Eur Neurol 2003;50:230-43
   PubMed Web of Science ®Google Scholar
• Goldstein DS. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol 2003;2:669-76
   PubMed Web of Science ®Google Scholar
• Matsui H, Nishinaka K, Oda M, et al. Does cardiac metaiodobenzylguanidine (MIBG) uptake in Parkinson's disease correlate with major autonomic symptoms? Parkinsonism Relat Disord 2006;12:284-8
   PubMed Web of Science ®Google Scholar
• Haapaniemi TH, Pursiainen V, Korpelainen JT, et al. Ambulatory ECG and analysis of heart rate variability in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001;70:305-10
   PubMed Web of Science ®Google Scholar
• Kallio M, Haapaniemi T, Turkka J, et al. Heart rate variability in patients with untreated Parkinson's disease. Eur J Neurol 2000;7:667-72
   PubMed Web of Science ®Google Scholar
• Devos D, Kroumova M, Bordet R, et al. Heart rate variability and Parkinson's disease severity. J Neural Transm 2003;110:997-1011
   PubMed Web of Science ®Google Scholar
• Goldstein DS, Holmes CS, Dendi R, et al. Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology 2002;58:1247-55
   PubMed Web of Science ®Google Scholar
• Quattrone A, Bagnato A, Annesi G, et al. Myocardial 123metaiodobenzylguanidine uptake in genetic Parkinson's disease. Mov Disord 2008;23:21-7
   PubMedGoogle Scholar
• Senard JM, Valet P, Durrieu G, et al. Adrenergic supersensitivity in parkinsonians with orthostatic hypotension. Eur J Clin Invest 1990;20:613-19
   PubMed Web of Science ®Google Scholar
• Barbic F, Perego F, Canesi M, et al. Early abnormalities of vascular and cardiac autonomic control in Parkinson's disease without orthostatic hypotension. Hypertension 2007;49:120-6
   PubMed Web of Science ®Google Scholar
• Benarroch EE, Schmeichel AM, Parisi JE. Involvement of the ventrolateral medulla in parkinsonism with autonomic failure. Neurology 2000;54:963-8
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K, Bratzke H, et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 2002;249(Suppl 3):1-5
   Google Scholar
• Bordet R, Benhadjali J, Destee A, et al. Sympathetic skin response and R-R interval variability in multiple system atrophy and idiopathic Parkinson's disease. Mov Disord 1996;11:268-72
   Google Scholar
• Friedrich C, Rudiger H, Schmidt C, et al. Baroreflex sensitivity and power spectral analysis during autonomic testing in different extrapyramidal syndromes. Mov Disord 2010;25:315-24
   PubMed Web of Science ®Google Scholar
• Iodice V, Low DA, Vichayanrat E, et al. Cardiovascular autonomic dysfunction in MSA and Parkinson's disease: similarities and differences. J Neurol Sci 2011;310:133-8
   PubMed Web of Science ®Google Scholar
• Wenning GK, Granata R, Krismer F, et al. Orthostatic hypotension is differentially associated with the cerebellar versus the parkinsonian variant of multiple system atrophy: a comparative study. Cerebellum 2012;11:223-6
   PubMed Web of Science ®Google Scholar
• Druschky A, Hilz MJ, Platsch G, et al. Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J Neurol Sci 2000;175:3-12
   PubMed Web of Science ®Google Scholar
• Kimber JR, Watson L, Mathias CJ. Distinction of idiopathic Parkinson's disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine. Lancet 1997;349:1877-81
   PubMedGoogle Scholar
• Pellecchia MT, Longo K, Pivonello R, et al. Multiple system atrophy is distinguished from idiopathic Parkinson's disease by the arginine growth hormone stimulation test. Ann Neurol 2006;60:611-15
   Google Scholar
• Lewis SJ, Pavese N, Rivero-Bosch M, et al. Brain monoamine systems in multiple system atrophy: a positron emission tomography study. Neurobiol Dis 2012;46:130-6
   PubMed Web of Science ®Google Scholar
• Nagayama H, Ueda M, Yamazaki M, et al. Abnormal cardiac [(123)I]-meta-iodobenzylguanidine uptake in multiple system atrophy. Mov Disord 2010;25:1744-7
   PubMed Web of Science ®Google Scholar
• Smith GD, Von Der Thusen J, Mathias CJ. Comparison of the blood pressure response to food in two clinical subgroups of multiple system atrophy (shy-drager syndrome). Parkinsonism Relat Disord 1998;4:113-17
   Google Scholar
• Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 2006;5:75-86
   PubMed Web of Science ®Google Scholar
• Maule S, Papotti G, Naso D, et al. Orthostatic hypotension: evaluation and treatment. Cardiovasc Hematol Disord Drug Targets 2007;7:63-70
   PubMedGoogle Scholar
• Thompson P, Wright J, Rajkumar C. Non-pharmacological treatments for orthostatic hypotension. Age Ageing 2011;40:292-3
   PubMed Web of Science ®Google Scholar
• Logan IC, Witham MD. Efficacy of treatments for orthostatic hypotension: a systematic review. Age Ageing 2012;41:587-94
   PubMed Web of Science ®Google Scholar
• O'Brien E, Parati G, Stergiou G, et al. European society of hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 2013;31:1731-68
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Toblli JE, Cardinali DP, et al. Nocturnal hypertension defined by fixed cut-off limits is a better predictor of left ventricular hypertrophy than non-dipping. Int J Cardiol 2008;127:387-9
   PubMed Web of Science ®Google Scholar
• Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the dublin outcome study. Hypertension 2005;46:156-61
   PubMed Web of Science ®Google Scholar
• Low PA, Singer W. Management of neurogenic orthostatic hypotension: an update. Lancet Neurol 2008;7:451-8
   PubMed Web of Science ®Google Scholar
• Low PA, Gilden JL, Freeman R, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine study group. JAMA 1997;277:1046-51
   PubMed Web of Science ®Google Scholar
• Seppi K, Weintraub D, Coelho M, et al. The Movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011;26(Suppl 3):S42-80
   PubMed Web of Science ®Google Scholar
• Shibao C, Okamoto L, Biaggioni I. Pharmacotherapy of autonomic failure. Pharmacol Ther 2012;134:279-86
   PubMed Web of Science ®Google Scholar
• Shibao C, Okamoto LE, Gamboa A, et al. Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. Hypertension 2010;56:847-51
   PubMed Web of Science ®Google Scholar
• Singer W, Sandroni P, Opfer-Gehrking TL, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 2006;63:513-18
   PubMed Web of Science ®Google Scholar
• Senard JM, Rascol O, Rascol A, et al. Lack of yohimbine effect on ambulatory blood pressure recording: a double-blind cross-over trial in parkinsonians with orthostatic hypotension. Fundam Clin Pharmacol 1993;7:465-70
   PubMed Web of Science ®Google Scholar
• Kaufmann H. L-dihydroxyphenylserine (droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience. Clin Auton Res 2008;18(Suppl 1):19-24
   PubMed Web of Science ®Google Scholar
• Goldstein DS. L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug. Cardiovasc Drug Rev 2006;24:189-203
   PubMed Web of Science ®Google Scholar
• Maruyama W, Naoi M, Narabayashi H. The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients. J Neurol Sci 1996;139:141-8
   PubMed Web of Science ®Google Scholar
• Goldstein DS, Holmes C, Kaufmann H, et al. Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure. Clin Auton Res 2004;14:363-8
   PubMed Web of Science ®Google Scholar
• Tohgi H, Abe T, Takahashi S, et al. Effect of a synthetic norepinephrine precursor, L-threo-3,4- dihydroxyphenylserine on the total norepinephrine concentration in the cerebrospinal fluid of parkinsonian patients. Neurosci Lett 1990;116:194-7
   PubMed Web of Science ®Google Scholar
• Holmes C, Whittaker N, Heredia-Moya J, et al. Contamination of the norepinephrine prodrug droxidopa by dihydroxyphenylacetaldehyde. Clin Chem 2010;56:832-8
   PubMed Web of Science ®Google Scholar
• Kurihara J, Takata Y, Suzuki S, et al. Effect of midodrine on chlorpromazine-induced orthostatic hypotension in rabbits: comparison with amezinium, etilefrine and droxidopa. Biol Pharm Bull 2000;23:1445-9
   PubMed Web of Science ®Google Scholar
• Iwase S, Mano T, Kunimoto M, et al. Effect of L-threo-3,4-dihydroxyphenylserine on muscle sympathetic nerve activity in humans. J Auton Nerv Syst 1992;39:159-67
   PubMedGoogle Scholar
• Jamnadas-Khoda J, Koshy S, Mathias CJ, et al. Are current recommendations to diagnose orthostatic hypotension in Parkinson's disease satisfactory? Mov Disord 2009;24:1747-51
   PubMed Web of Science ®Google Scholar
• Freeman R, Young J, Landsberg L, et al. The treatment of postprandial hypotension in autonomic failure with 3,4-DL-threo-dihydroxyphenylserine. Neurology 1996;47:1414-20
   PubMed Web of Science ®Google Scholar
• Freeman R, Landsberg L, Young J. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial. Neurology 1999;53:2151-7
   PubMed Web of Science ®Google Scholar
• Mathias CJ, Senard JM, Braune S, et al. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res 2001;11:235-42
   PubMed Web of Science ®Google Scholar
• Kaufmann H, Saadia D, Voustianiouk A, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation 2003;108:724-8
   PubMed Web of Science ®Google Scholar
• Mathias CJ. L-dihydroxyphenylserine (droxidopa) in the treatment of orthostatic hypotension: the european experience. Clin Auton Res 2008;18(Suppl 1):25-9
   PubMed Web of Science ®Google Scholar
• Mathias C, Low P, Freeman A, et al. Integrated efficacy analysis of droxidopa in 2 double-blind, placebo-controlled phase 3 studies in patients with neurogenic orthostatic hypotension. Mov Disord 2012;27(Suppl 1):1296
   Google Scholar
• Isaacson S, Hauser R, Szakacs CBN, et al. Impact of droxidopa treatment in patients with Parkinson's disease and symptomatic neurogenic orthostatic hypotension (study 306). Mov Disord 2013;28(Suppl 1):468
   Google Scholar
• Hauser RA, Isaacson S. Impact of treatment with droxidopa in repeat fallers with Parkinson's disease and symptomatic neurogenic orthostatic hypotension (NOH 306A). Mov Disord 2012;27(Suppl 1):S423
   Google Scholar
• Biaggioni I, Robertson RM. Hypertension in orthostatic hypotension and autonomic dysfunction. Cardiol Clin 2002;20:291-301. vii
   PubMedGoogle Scholar
• Goldstein DS, Holmes C, Sewell L, et al. Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS. J Clin Pharmacol 2011;51:66-74
   PubMed Web of Science ®Google Scholar
• Iida N, Koshikawa S, Akizawa T, et al. Effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients. Am J Nephrol 2002;22:338-46
   PubMed Web of Science ®Google Scholar
• Fujisaki K, Kanai H, Hirakata H, et al. Midodrine hydrochloride and L-threo-3,4-dihydroxy-phenylserine preserve cerebral blood flow in hemodialysis patients with orthostatic hypotension. Ther Apher Dial 2007;11:49-55
   PubMed Web of Science ®Google Scholar
• Wecht JM, Rosado-Rivera D, Weir JP, et al. Hemodynamic effects of L-threo-3,4-dihydroxyphenylserine (droxidopa) in hypotensive individuals with spinal cord injury. Arch Phys Med Rehabil 2013;94:2006-12
   Google Scholar
• Tanaka H, Yamaguchi H, Mino M. The effects of the noradrenaline precursor, L-threo-3,4-dihydroxyphenylserine, in children with orthostatic intolerance. Clin Auton Res 1996;6:189-93
   PubMed Web of Science ®Google Scholar
• Gibbons CH, Vernino SA, Kaufmann H, et al. L-DOPS therapy for refractory orthostatic hypotension in autoimmune autonomic neuropathy. Neurology 2005;65:1104-6
   PubMed Web of Science ®Google Scholar
• Fornai F, di Poggio AB, Pellegrini A, et al. Noradrenaline in Parkinson's disease: from disease progression to current therapeutics. Curr Med Chem 2007;14:2330-4
   PubMed Web of Science ®Google Scholar
• Fukada K, Endo T, Yokoe M, et al. L-threo-3,4-dihydroxyphenylserine (L-DOPS) co-administered with entacapone improves freezing of gait in Parkinson's disease. Med Hypotheses 2013;80:209-12
   PubMed Web of Science ®Google Scholar
• Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A). J Parkinsons Dis 2014;4(1):57-65
   PubMedGoogle Scholar
• Quinn NP, Luthert P, Honavar M, et al. Pure akinesia due to lewy body Parkinson's disease: a case with pathology. Mov Disord 1989;4:85-9
   PubMed Web of Science ®Google Scholar
• Kawabata A, Kasamatsu K, Umeda N, et al. The noradrenaline precursor L-threo-3,4-dihydroxyphenylserine exhibits antinociceptive activity via central alpha-adrenoceptors in the mouse. Br J Pharmacol 1994;111:503-8
   Google Scholar
• Takagi H, Harima A. Analgesic effect of L-threo-3,4-dihydroxyphenylserine (L-DOPS) in patients with chronic pain. Eur Neuropsychopharmacol 1996;6:43-7
   Google Scholar
• Kalinin S, Polak PE, Lin SX, et al. The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease. Neurobiol Aging 2012;33:1651-63
   Google Scholar
• Harada H, Noto T, Tsuji M, et al. Effects of L-threo- and erythro-3,4-dihydroxyphenylserine on learning performance and concentrations of brain noradrenaline and its metabolites in rats. Pharmacol Biochem Behav 1992;43:215-21
   Google Scholar
• Donsante A, Sullivan P, Goldstein DS, et al. L-threo-dihydroxyphenylserine corrects neurochemical abnormalities in a menkes disease mouse model. Ann Neurol 2013;73:259-65
   Google Scholar
• Coll M, Rodriguez S, Raurell I, et al. Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats. Hepatology 2012;56:1849-60
   Google Scholar
• Perez-Lloret S, Rey MV, Pavy-Le Traon A, et al. Emerging drugs for autonomic dysfunction in Parkinson's disease. Expert Opin Emerg Drugs 2013;18:39-53
   PubMed Web of Science ®Google Scholar